Crispr Therapeutics price target raised to $82 from $80 at Needham

Core Viewpoint - Needham raised the price target on Crispr Therapeutics (CRSP) to $82 from $80 while maintaining a Buy rating after the company's Q4 results [1] Group 1: Financial Performance - Casgevy sales in 2025 are projected to reach $116 million, surpassing Vertex's target of approximately $100 million [1]